Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 8/20 | 0.36 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17723382 | 0.84 | ENPP2 (0.48) | ENPP2HDAC4HDAC1HDAC6 | |
| SCHEMBL20021789 | 0.80 | HDAC4 (0.44) | EGFRHDAC4HDAC1HDAC6 | |
| SCHEMBL17723367 | 0.76 | PDPK1 (0.38) | EGFRHDAC4HDAC1HDAC6 | |
| SCHEMBL17723372 | 0.75 | EGFR (0.44) | MAPKAPK2ESR1ESR2PDCD1CD274 | |
| SCHEMBL17723397 | 0.75 | EGFR (0.44) | MAPKAPK2ESR1ESR2PDCD1CD274 | |
| SCHEMBL17723306 | 0.69 | JAK2 (0.33) | — | |
| SCHEMBL5951002 | 0.67 | CHRNA7 (0.37) | — | |
| SCHEMBL17723359 | 0.67 | ATP1A1 (0.43) | ENPP2 | |
| SCHEMBL17723351 | 0.67 | PSEN1 (0.43) | ENPP2EGFRHDAC6 | |
| SCHEMBL17723304 | 0.66 | ALK (0.39) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117884-B2 | Potent gamma-secretase modulators | THE GENERAL HOSPITAL CORPORATION (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200055840-A1 | POTENT GAMMA-SECRETASE MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-20 | — | — | US | disclosed |
| US-10472346-B2 | Potent gamma-secretase modulators | THE GENERAL HOSPITAL CORPORATION (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180093967-A1 | POTENT GAMMA-SECRETASE MODULATORS | THE GENERAL HOSPITAL CORPORATION | 2018-04-05 | — | — | US | disclosed |
| WO-2016070107-A1 | POTENT GAMMA-SECRETASE MODULATORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055840-A1 | POTENT GAMMA-SECRETASE MODULATORS | BACE1, BACE2, GSAP | MAPKAPK2 1621/4885ESR1 2244/4885ESR2 520/4885 |
| US-10472346-B2 | Potent gamma-secretase modulators | BACE1, BACE2, APP | MAPKAPK2 2811/4885ESR1 2184/4885ESR2 719/4885 |
| US-11117884-B2 | Potent gamma-secretase modulators | BACE1, BACE2, GSAP | MAPKAPK2 1621/4885ESR1 2244/4885ESR2 520/4885 |
| US-20180093967-A1 | POTENT GAMMA-SECRETASE MODULATORS | BACE1, BACE2, APP | MAPKAPK2 2811/4885ESR1 2184/4885ESR2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.